Form 4: Myriad Genetics CEO Paul Diaz Sells 15,000 Shares
SEC Form 4 Filing
Paul J. Diaz, President and CEO of Myriad Genetics, sold 15,000 shares of common stock on October 11, 2024, at a price of $22.93 per share.
Summary
- Paul J. Diaz, the President and CEO of Myriad Genetics, sold 15,000 shares of the company's common stock on October 11, 2024.
- The sale was executed at a price of $22.93 per share.
- Following the transaction, Diaz directly owns 962,378 shares of Myriad Genetics.
- The sale was conducted under a pre-arranged Rule 10b5-1 trading plan.
Sentiment
Score: 5
Explanation: The document is a standard SEC Form 4 filing, reporting an insider stock sale. It doesn't inherently convey positive or negative sentiment, but the market may interpret the sale in light of other information.
Industry Context
Insider sales are a common occurrence and are often scrutinized by investors for insights into management's perspective on the company's valuation and future prospects. However, sales under 10b5-1 plans are less likely to be indicative of management sentiment as they are pre-arranged.
Stakeholder Impact
- The stock sale could potentially influence shareholder sentiment, depending on how the market interprets the transaction.
Key Dates
| Date | Description |
|---|---|
| 10/11/2024 | Date of the stock sale transaction. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.